## ARTICLE IN PRESS

Clinica Chimica Acta xxx (2008) xxx-xxx



Contents lists available at ScienceDirect

## Clinica Chimica Acta



journal homepage: www.elsevier.com/locate/clinchim

### Letter to the Editor

# Association of chronic stable angina pectoris with MCP-1-2518 A/G single nucleotide polymorphism in the Slovak population

#### Dear Editor,

1 2

3

Δ

Inflammation and genetic factors are both prominent mechanisms in the pathogenesis of atherosclerosis and atherothrombosis - one of the leading causes of coronary artery disease (CAD). A number of 10 population studies have explored the association of CAD with gene 11 polymorphisms of different inflammatory molecules [1]. In this regard, monocyte chemoattractant protein-1 (MCP-1, also known as 12CCL2) and its receptor CCR2 have been proposed as candidate genes 13 for investigating the genetic markers in CAD [1–4]. In this study we, 14therefore, explored the relationship between a functional MCP-1 gene 15polymorphism and chronic stable angina pectoris as a representative 16example of CAD. 17

Our case control study comprised 151 patients with chronic stable
angina pectoris (AP) (62 males / 89 females, mean age 61±9.7 / 64±
7.6 years). The population control group comprised 449 unrelated
healthy subjects recruited from persons of Slovak origin without
symptoms of cardiac or other inflammatory pathologies (284 males /
165 females, mean age 50±10.7 years / 48±9.6 years).

Angina pectoris was defined as chronic intermittent ischemia 24 25 presenting with typical chest pain, ECG ST segment deviation (exercise test. Holter or ECG at rest) and response to antiangose therapy. A **O2**26 complete personal and medical history was taken by gualified 27physicians. The parameters analysed were whole blood count, lipid 2829profile, glucose, total antioxidant status, homocysteine and vitamin B status, inflammatory markers and several oxidative stress parameters. 30 Subjects in whom AP was diagnosed according to the above criteria 31 were considered patients, apparently healthy subjects were consid-32 33 ered controls. Cardiovascular symptomatology in the control subjects

was also evaluated according to the standard Rose questionnaire [5] 34 and in 55% of control subjects by exercise electrocardiography. 35

Patients and control subjects were unrelated and of Caucasian 36 origin. The study was approved by the local Ethics Committee (School 37 of Medicine, Comenius University, Bratislava) and all subjects signed 38 an informed consent. 39

After DNA extraction by a standard salting out procedure [6], the 40 MCP-1 wild-type (A) and mutant (G) alleles were typed using poly- 41 merase chain reaction with sequence specific primers (PCR-SSP) [7,8]. 42 The sequences of specific primers were: allele A, forward: 5'GTG GGA 43 GGC AGA CAG CTA; allele G, forward: 5' GTG GGA GGC AGA CAG ATG; 44 constant reverse: 5'TGA GTG TTC ACA TAG GCT TC. MCP-1-2518 45 genotypes were assessed according to the presence/absence of PCR 46 amplicons specific to the particular alleles in a standard 2% agarose gel 47 stained with ethidium-bromide.

The genotype, allele frequencies, as well as carriage rate (pheno- 49 type frequency) in the patient and control populations were compared 50 using a standard  $2 \times 2 \chi^2$  test using SIGTEST with Woolf–Haldane 51 correction. The chi-squared statistic, 95% confidential interval and the 52 relative risk (odds ratio – OR) were also calculated. The population 53 samples were tested for conformity to the Hardy–Weinberg equili- 54 brium (HWE). 55

The healthy control group was within the HWE with regard to 56 distribution of the MCP-1-2518 A/G genotypes (P>0.05). The group of 57 AP patients deviated from HWE owing to higher frequency of GG 58 genotype and lower frequency of AG heterozygotes (P<0.001). 59

Mutant GG genotype was over-represented in AP patients (15.2%) 60 in comparison to the controls (5.8%) (*P*=0.003) [Table 1]. The patients 61 were then further divided into subgroups according to the first 62

#### t1.1 Table 1

t1.2 Distribution of MCP-1-2518 A/G genotype frequencies in Slovak patients with chronic stable AP and in Slovak healthy control population

t1.3	Study group	Genotypes			Statistics (significant values in bold)			
t1.4	Patients with:	AA	AG	GG	<i>P</i> =	95% C.I.	OR/Etiologic fraction	$\chi^2$
t1.5	AP (n=151)	58.3% ( <i>n</i> =88)	26.5% ( <i>n</i> =40)	15.2% ( <i>n</i> =23)	0.003	1.414 - 4.746	2.590/12.8%	9.489
t1.6	Early AP $(n=72)$	63.9% ( <i>n</i> =46)	20.8% (n = 15)	15.3% (n = 11)	0.022	1.129 - 5.155	2.412/11.2%	5.168
t1.7	Late AP $(n=61)$	50.8% (n=31)	36.1%(n=22)	13.1%(n=8)	0.025	1.118 - 6.199	2.632/12.5%	4.904
t1.8	Controls $(n=449)$	57.5% (n=258)	36.7% (n=165)	5.8% (n=26)				
t1.9	AP in men $(n=62)$	58.0% (n=36)	22.6% (n = 14)	19.4% (n = 12)	0.002	1.568 - 7.119	3.341/17.5%	9.764
t1.10	AP in women $(n=89)$	58.4% (n=52)	29.3% (n=26)	$\frac{12:4\%}{12:4\%}$ (n = 11)	0.046	1.006 - 4.537	2.137/9.2%	3.906
t1.11	Early AP in men $(n=30)$	56.7% (n = 17)	20.0% (n=6)	23.3%(n=7)	0.003	1.626 - 10.747	4.181/22.1%	8.817
t1.12	Early AP-women $(n=42)$	69.0% ( <i>n</i> =29)	21.4% (n=9)	9.5% (n=4)	0.526	0.511 - 4.336	1.488/3.3%	0.531
t1.13	Late AP in men $(n=24)$	54.2% (n = 13)	29.2% (n=7)	16.7% (n=4)	0.040	1.041 - 10.160	3.252/15.9%	4.115
t1.14	Late AP in women $(n=37)$	48.6% ( <i>n</i> =18)	40.5% (n=15)	10.8% (n=4)	0.122	0.786 - 7.164	2.373/10.0%	2.349
t1.15	Controls in men $(n=284)$	52.8% ( <i>n</i> =150)	40.5% ( <i>n</i> =115)	6.7% (n=19)	0.157	0.779 – <del>4.50</del>	<del>81.874</del> /5.6%	1.969
t1.16	Controls in women ( <i>n</i> =165)	65.6% ( <i>n</i> = 108)	30.3% ( <i>n</i> =50)	4.2% ( <i>n</i> =7)			-	

t1.17 Legend: AP, chronic stable angina pectoris; C.I., confidence interval; OR, odds ratio.

0009-8981/\$ - see front matter © 2008 Published by Elsevier B.V. doi:10.1016/j.cca.2008.03.001

Please cite this article as: Bucova M, et al, Association of chronic stable angina pectoris with MCP-1-2518 A/G single nucleotide polymorphism in the Slovak population, Clin Chim Acta (2008), doi:10.1016/j.cca.2008.03.001

2

#### Letter to the Editor

appearance of AP symptoms (early AP:  $\leq$  50 years; late AP: > 50 years) 63 64 and gender. In comparison with healthy population, higher rate of GG homozygous genotype was characteristic both for patients with early 65 66 (15.3%)(P=0.022) as well as late AP(13.1%)(P=0.025) and was present in both male (23.3%) (P=0.003) and female (16.7%) (P=0.040) AP 67 patients. The significance was higher for men than women. There 68 69 were no significant differences either in allele frequencies or carriage 70 rates between patient or control groups.

Though data on the contribution of the MCP-1-2518 A/G single 7172nucleotide polymorphism (SNP) to the pathogenesis of coronary atherosclerosis are heterogeneous [2,4,8], the current view is that this 73SNP is associated with severe CAD [2], myocardial infarction [9] and 74occult ischemia in a high-risk asymptomatic population [4]. The 75functional relevance of the MCP-1 SNP was revealed by its association 76with MCP-1 plasma levels [10]. 77

78 In aggregate, our results are in line with these observations. The frequency of mutant GG genotype in Slovak patients with AP was 79 significantly higher than in control subjects and it was also more 80 frequent in men than women. We conclude that chronic stable angina 81 pectoris in Slovak patients is linked to MCP-1-2518 (A/G) single 82 nucleotide polymorphism and that inflammatory processes have 83 important roles in the aetiology of this disease. 84

#### Acknowledgements 85

This work was supported by the grant VEGA 1/0528/03 and also in 86 part by Czech and Slovak Ministries of Schools and Education, projects 87

Kontakt 1/SK-CZ-02806, MSM6198959205 and ME-856. 88

#### References 89

- 90 [1] Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: 91 recent evidence from experimental models and population genetics. Curr Opin 92Lipidol 2004.15.145-9
- 93 [2] Szalai C, Duba J, Prohászka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). 94 95 Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. 96 Atherosclerosis 2001;158:233-9.
- 97 [3] Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2 -/- mice 98 reveals a role for chemokines in the initiation of atherosclerosis. Nature 99 1998:394:894-7
- 100 Kim MP, Wahl LM, Yanek LR, Becker DM, Becker LC. A monocyte chemoattractant 101 protein-1 gene polymorphism is associated with occult ischemia in a high-risk 102 asymptomatic population. Atherosclerosis 2007;193:366-72.
- 103 Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health 104 Organ 1968:56:1-188
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA 105[6] 106 from human nucleated cells. Nucleic Acids Res 1988:16:1215. 149

- [7] Bunce M, O'Neil CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing 107 for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DOB1 by PCR with 144 primer mixes 108 utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-67. 109
- Cermakova Z, Petrkova J, Arakelyan A, et al. The MCP-1-2518 (A to G) single 110 nucleotide polymorphism is not associated with myocardial infarction in the 111 Czech population. Int J Immunogenet 2005;32:315-8. 112
- McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated 113 [9] with serum monocyte chemoattractant protein-1 levels and myocardial infarction 114 in the Framingham heart study. Circulation 2005;112:1113-20. 115
- [10] Tabara Y, Kohara K, Yamamoto Y, et al. Polymorphism of the monocyte chemoat- 116 tractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not 117 with carotid intima-media thickness. Hypertens Res 2003;26:677-83. 118
  - 119
  - Maria Bucova 120 Department of Immunology, School of Medicine, 121
  - Comenius University, Sasinkova ul. 4, 811 08 Bratislava, Slovakia 122
    - Corresponding author. Tel.: +421 59 357 351; 123
      - fax: +421 59 357 578. 124
      - *E-mail address:* maria.bucova@gmail.com, 125 Q1
        - maria.bucova@fmed.uniba.sk. 126
    - Jan Lietava 127 Department of Internal Medicine II, School of Medicine, 128
      - Comenius University, Bratislava, Slovakia 129
      - E-mail address: jan.lietava@orangemail.sk. 130
        - Frantisek Mrazek 131
        - Martin Petrek 132 Laboratory of Immunogenomics, 133
      - Palacky University Olomouc, Czech Republic 134
    - E-mail address: frantisek.mrazek@fnol.cz (F. Mrazek), 135
      - martinpe@email.cz (M. Petrek). 136
        - Jana Petrkova 137
      - Department of Internal Medicine I, 138
      - Faculty Hospital Olomouc, Czech Republic 139
      - E-mail address: jana.petrekova@fnol.cz. 140
        - Marian Bernadic 141
    - Department of Pathological Physiology, School of Medicine, 142
      - Comenius University. Bratislava. Slovakia 143
      - E-mail address: marian.bernadic@fmed.uniba.sk. 144

Thomas Buckingham 145

National Institute of Heart Disease, Bratislava, Slovakia 146 *E-mail address:* thomas.buckingham@fmed.uniba.sk. 147

13 February 2008 148